These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 29040662)
41. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929 [TBL] [Abstract][Full Text] [Related]
44. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203 [TBL] [Abstract][Full Text] [Related]
45. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas. Nishikawa T; Ohka F; Aoki K; Suzuki H; Motomura K; Yamaguchi J; Maeda S; Kibe Y; Shimizu H; Natsume A; Innan H; Saito R Brain Tumor Pathol; 2023 Apr; 40(2):85-92. PubMed ID: 36991274 [TBL] [Abstract][Full Text] [Related]
46. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981 [TBL] [Abstract][Full Text] [Related]
47. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes. Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676 [TBL] [Abstract][Full Text] [Related]
48. Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C. Eckel-Passow JE; Drucker KL; Kollmeyer TM; Kosel ML; Decker PA; Molinaro AM; Rice T; Praska CE; Clark L; Caron A; Abyzov A; Batzler A; Song JS; Pekmezci M; Hansen HM; McCoy LS; Bracci PM; Wiemels J; Wiencke JK; Francis S; Burns TC; Giannini C; Lachance DH; Wrensch M; Jenkins RB Neuro Oncol; 2020 Nov; 22(11):1602-1613. PubMed ID: 32386320 [TBL] [Abstract][Full Text] [Related]
49. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted. Santosh V; Rao S Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130 [TBL] [Abstract][Full Text] [Related]
50. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
51. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related]
52. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
53. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142 [TBL] [Abstract][Full Text] [Related]
54. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
55. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma. Mamatjan Y; Voisin MR; Nassiri F; Moraes FY; Bunda S; So J; Salih M; Shirahata M; Ono T; Shimizu H; Schrimpf D; von Deimling A; Aldape KD; Zadeh G Neuro Oncol; 2023 Nov; 25(11):2028-2041. PubMed ID: 37474126 [TBL] [Abstract][Full Text] [Related]
56. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840 [TBL] [Abstract][Full Text] [Related]
57. Molecular subtypes of glioblastoma are relevant to lower grade glioma. Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622 [TBL] [Abstract][Full Text] [Related]
58. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974 [TBL] [Abstract][Full Text] [Related]
59. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778 [TBL] [Abstract][Full Text] [Related]
60. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]